Dr Spigel talks to ecancer about results from an international clinical trial he presented at ASCO 2025.

The study showed that a 14-gene molecular assay can help identify patients with early-stage non-squamous non-small cell lung cancer (NSCLC) who could benefit from adjuvant chemotherapy after surgery.

Dr Spigel notes that this is the first large prospective randomized trial to demonstrate that a 14-gene molecular assay can identify who could benefit from adjuvant chemotherapy among a high-risk group of patients with stage IA-IIA non-squamous non-small cell lung cancer who otherwise may not typically receive such therapy.